Cell-Specific Expression of Human SIRT1 by Gene Therapy Reduces Retinal Ganglion Cell Loss Induced by Elevated Intraocular Pressure
Authors:
- 26 March 2023
- journal article
- research article
- Published by Elsevier in Neurotherapeutics
- Vol. 20 (3) , 896-907
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Health (EY019014, EY301163)
- Harold Amos Faculty Development Award
- Research to Prevent Blindness
- Foundation Fighting Blindness
- Paul MacKall and Evanina Bell MacKall Trust
- Center for Advanced Retinal and Ocular Therapeutics, Perelman School of Medicine, University of Pennsylvania
- F. M. Kirby Foundation
This publication has 33 references indexed in Scilit:
- SIRT1 Activating compounds reduce oxidative stress mediated neuronal loss in viral induced CNS demyelinating diseaseActa Neuropathologica Communications, 2014
- Resveratrol Neuroprotection in a Chronic Mouse Model of Multiple SclerosisFrontiers in Neurology, 2012
- Oral Resveratrol Reduces Neuronal Damage in a Model of Multiple SclerosisJournal of Neuro-Ophthalmology, 2010
- Rodent models of glaucomaBrain Research Bulletin, 2010
- The Microbead Occlusion Model: A Paradigm for Induced Ocular Hypertension in Rats and MiceInvestigative Ophthalmology & Visual Science, 2010
- Does elevated intraocular pressure reduce retinal TRKB-mediated survival signaling in experimental glaucoma?Experimental Eye Research, 2009
- Progressive Ganglion Cell Degeneration Precedes Neuronal Loss in a Mouse Model of GlaucomaThe Journal of Neuroscience, 2008
- SIRT1 Activation Confers Neuroprotection in Experimental Optic NeuritisInvestigative Ophthalmology & Visual Science, 2007
- Temba glaucoma study: a population-based cross-sectional survey in urban South AfricaOphthalmology, 2003
- Risk factors for noncompliance with glaucoma follow-up visits in a residents’ eye clinicOphthalmology, 1998